Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
$221.38
+0.0%
$220.96
$18.51
$221.42
$6.96B1.52928,762 shs2.69 million shs
Insmed, Inc. stock logo
INSM
Insmed
$107.02
-1.2%
$105.79
$90.39
$212.75
$23.48B0.782.90 million shs2.02 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$59.49
-3.8%
$58.00
$22.28
$85.60
$24.53B0.948.27 million shs4.95 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$34.05
-1.3%
$31.78
$10.90
$37.00
$24.82B1.115.80 million shs6.01 million shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
0.00%0.00%0.00%0.00%+269.21%
Insmed, Inc. stock logo
INSM
Insmed
-1.20%-1.94%+11.83%-24.09%+4.35%
Moderna, Inc. stock logo
MRNA
Moderna
-3.77%-11.22%-6.99%+9.70%+90.31%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-1.33%-1.33%+8.34%+16.25%+197.64%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
$221.38
+0.0%
$220.96
$18.51
$221.42
$6.96B1.52928,762 shs2.69 million shs
Insmed, Inc. stock logo
INSM
Insmed
$107.02
-1.2%
$105.79
$90.39
$212.75
$23.48B0.782.90 million shs2.02 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$59.49
-3.8%
$58.00
$22.28
$85.60
$24.53B0.948.27 million shs4.95 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$34.05
-1.3%
$31.78
$10.90
$37.00
$24.82B1.115.80 million shs6.01 million shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
0.00%0.00%0.00%0.00%+269.21%
Insmed, Inc. stock logo
INSM
Insmed
-1.20%-1.94%+11.83%-24.09%+4.35%
Moderna, Inc. stock logo
MRNA
Moderna
-3.77%-11.22%-6.99%+9.70%+90.31%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-1.33%-1.33%+8.34%+16.25%+197.64%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
2.30
Hold$169.88-23.27% Downside
Insmed, Inc. stock logo
INSM
Insmed
2.96
Moderate Buy$209.1395.41% Upside
Moderna, Inc. stock logo
MRNA
Moderna
1.82
Reduce$38.80-34.78% Downside
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
2.75
Moderate Buy$33.59-1.35% Downside

Current Analyst Ratings Breakdown

Latest CDTX, MRNA, ROIV, and INSM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/20/2026
Insmed, Inc. stock logo
INSM
Insmed
Initiated CoverageOutperform$192.00
7/20/2026
Insmed, Inc. stock logo
INSM
Insmed
Reiterated RatingBuy$220.00
7/20/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingUnderperform$25.00
7/15/2026
Insmed, Inc. stock logo
INSM
Insmed
Boost Price TargetOverweight$160.00 ➝ $161.00
7/10/2026
Insmed, Inc. stock logo
INSM
Insmed
Reiterated RatingBuy$207.00
7/8/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetEqual Weight$33.00 ➝ $39.00
7/7/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetSector Perform$38.00 ➝ $45.00
7/7/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetUnderperform$34.00 ➝ $38.00
6/26/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetOverweight$69.00 ➝ $77.00
6/18/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingHold
6/16/2026
Insmed, Inc. stock logo
INSM
Insmed
Set Price Target$192.00
(Data available from 7/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
N/AN/AN/AN/A$14.92 per shareN/A
Insmed, Inc. stock logo
INSM
Insmed
$606.42M38.25N/AN/A$3.46 per share30.93
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B12.14N/AN/A$22.14 per share2.69
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$8.26M2,965.03N/AN/A$7.35 per share4.63
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-$169.83M-$11.78N/AN/AN/AN/A-45.52%-38.31%N/A
Insmed, Inc. stock logo
INSM
Insmed
-$1.28B-$5.75N/A178.37N/A-144.44%-130.11%-51.57%8/6/2026 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$8.15N/AN/AN/A-143.55%-26.64%-19.32%7/31/2026 (Estimated)
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$299.77M-$0.60N/AN/AN/A-3,629.19%-20.54%-19.43%8/10/2026 (Estimated)

Latest CDTX, MRNA, ROIV, and INSM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q1 2027
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$0.33N/AN/AN/A$2.07 millionN/A
8/6/2026Q2 2026
Insmed, Inc. stock logo
INSM
Insmed
-$0.70N/AN/AN/A$392.53 millionN/A
7/31/2026Q2 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$2.0355N/AN/AN/A$103.10 millionN/A
5/7/2026Q1 2026
Insmed, Inc. stock logo
INSM
Insmed
-$0.90-$0.76+$0.14-$0.76$300.81 million$305.96 million
5/1/2026Q1 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$3.02-$3.40-$0.38-$3.40$236.37 million$389.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
N/AN/AN/AN/AN/A
Insmed, Inc. stock logo
INSM
Insmed
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
N/A
4.62
4.62
Insmed, Inc. stock logo
INSM
Insmed
0.80
4.47
4.10
Moderna, Inc. stock logo
MRNA
Moderna
0.08
2.41
2.35
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/A
18.37
18.37

Institutional Ownership

CompanyInstitutional Ownership
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
35.82%
Insmed, Inc. stock logo
INSM
Insmed
N/A
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
64.76%

Insider Ownership

CompanyInsider Ownership
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
3.89%
Insmed, Inc. stock logo
INSM
Insmed
2.10%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
10.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
9031.44 million30.22 millionNo Data
Insmed, Inc. stock logo
INSM
Insmed
1,664216.75 million212.20 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700396.79 million353.93 millionOptionable
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
860719.27 million641.59 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Cidara Therapeutics stock logo

Cidara Therapeutics NASDAQ:CDTX

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Insmed stock logo

Insmed NASDAQ:INSM

$107.02 -1.30 (-1.20%)
Closing price 07/20/2026 04:00 PM Eastern
Extended Trading
$107.40 +0.38 (+0.36%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Moderna stock logo

Moderna NASDAQ:MRNA

$59.49 -2.33 (-3.77%)
Closing price 07/20/2026 04:00 PM Eastern
Extended Trading
$59.84 +0.34 (+0.58%)
As of 04:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Roivant Sciences stock logo

Roivant Sciences NASDAQ:ROIV

$34.05 -0.46 (-1.33%)
Closing price 07/20/2026 04:00 PM Eastern
Extended Trading
$34.32 +0.27 (+0.79%)
As of 04:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.